Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870663 | 0.90 | TSHR (0.32) | ALDH1A1TSHRBTN3A1 | |
| SCHEMBL2859462 | 0.82 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2864117 | 0.78 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL10826114 | 0.77 | DGKA (0.57) | ALDH1A1TSHRHPGDATMNAAA | |
| SCHEMBL6883385 | 0.73 | TSHR (0.52) | ALDH1A1TSHRHPGDBTN3A1 | |
| SCHEMBL2860817 | 0.73 | TSHR (0.33) | TSHR | |
| SCHEMBL10573305 | 0.72 | DGKA (0.60) | ALDH1A1TSHRL3MBTL1NAAADGKA | |
| SCHEMBL108471 | 0.71 | — | — | |
| SCHEMBL10826473 | 0.70 | DGKA (0.63) | ALDH1A1TSHRNAAADGKA | |
| SCHEMBL10410456 | 0.70 | DGKA (0.63) | ALDH1A1TSHRNAAADGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728180-B2 | Method for producing ethers | KURARAY CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080262272-A1 | Method For Producing Ethers | KURARAY CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| CN-1972888-A | Method for producing ethers | KURARAY CO (JP) | 2007-05-30 | — | — | CN | disclosed |
| EP-1760061-A1 | METHOD FOR PRODUCING ETHERS | KURARAY CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262272-A1 | Method For Producing Ethers | TELO2, PDS5A, TERT | ALDH1A1 3068/4885TSHR 657/4885HPGD 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.